GLP-1 + growth hormone compound
Two drugs that do not interact, and one question nobody has answered.
Semaglutide and tirzepatide are the drugs sold as Ozempic, Wegovy, Mounjaro and Zepbound. Some of the weight they take off is muscle, so people add a second compound to hold onto it.
The muscle comes off with the fat.
GLP-1 drugs suppress appetite hard, weight comes off, and some of what comes off is muscle. Growth hormone signaling is associated with holding lean tissue, so a compound that raises your own growth hormone should offset the loss. That is the whole argument, and it is a reasonable one.
The two drugs work on completely different targets and do not touch each other.[7] So this stack carries none of the interaction worries that come up elsewhere.
Four benefits, and how well each one holds up.
Only the bottom row has trial evidence behind it, and that belongs to the drug people were already taking. Everything the second compound gets added for sits in the three rows above it.
Three questions, answered before anything else.
Muscle is the stated reason and it is rarely the only one. Ipamorelin and CJC-1295 are the most established pairing in growth hormone peptides, run for deeper sleep and faster recovery from training long before GLP-1 drugs existed. People on a calorie deficit are often sleeping badly and training poorly, so those effects land on exactly the complaints a deficit produces. Ipamorelin is also the selective one in its class. It triggers the growth hormone pulse without raising hunger or stress hormones, which older compounds did. That matters more than usual here, since appetite control is the point of the other drug.
Two different measurements, told apart.
Published figures measure two different things. Quoting them side by side is how most pages get this wrong, so here they are separated.
Both framings appear in the same articles, often in the same paragraph, as if they were one number.
The largest real-world look covered 670,422 people starting a GLP-1. Of those, 7,965 had lean body mass measured before and after, mostly with impedance meters, the same method a smart scale uses. Tirzepatide produced a steeper decline than semaglutide in routine care.[4] That is a preprint and the measurement method varied across patients.
Not everyone calls this a problem. One clinical view holds that it is the body adjusting to being smaller, not muscle wasting.[8] Most of what comes off is still fat. A smaller body needs less muscle to carry it. There is something to that. It holds up less well for older adults, and for anyone who did not have much muscle to begin with.
Both halves have been studied. The join has not.
No published randomized trial has tested ipamorelin, CJC-1295 or any related secretagogue combined with semaglutide or tirzepatide.[7] Approval of a compound on its own carries no information about how it behaves alongside another.
The strongest evidence that the problem is real.
Share of total weight lost that was muscle instead of fat. One group got a drug that blocks myostatin, the body's own brake on muscle growth. The other got a dummy injection. Both groups lost the same total weight.[1] apitegromab is a monoclonal antibody, not a peptide anyone can buy.
A phase 2 trial is the mid-stage point, where a drug is first tested for real effect in a few hundred people. A pharmaceutical company paying for one is a stronger signal that the problem is real than any amount of forum discussion. The authors called the study small and noted several limitations. The trial establishes that the target matters. It says nothing about whether ipamorelin reaches it.
The useful comparison is against what already works.
Two interventions have randomized human evidence for preserving lean mass during weight loss, and both are free.
Human randomized evidence
- Resistance training during weight loss
- Adequate protein intake alongside it
- Myostatin inhibition, one phase 2 trial, drug not available to consumers
Mechanism only
- Ipamorelin alongside a GLP-1
- CJC-1295 alongside a GLP-1
- Any secretagogue adding benefit on top of training and protein
The clearest trial put 100 adults aged 55 to 80 into four groups for ten weeks of weight loss. Higher protein or normal protein, each with or without resistance training three times a week. Only the group doing both increased fat-free mass, by 0.6 kg.[10] Neither intervention alone managed it.
A meta-analysis found strength rising 0.72 percent for every 0.1 g/kg of body weight added to daily protein, up to about 1.5 g/kg. Past that, nothing more. It also found that protein alone, without resistance training, does not increase strength at all.[11]
Neither of those trials was run in people taking a GLP-1, and that gap is being closed right now. Two trials are recruiting. One measures muscle directly, using ultrasound and a tracer.[5] The other puts 232 people into four groups, testing resistance exercise and protein during semaglutide or tirzepatide treatment.[12]
The protocol for that second trial says two things plainly. Nobody has studied resistance exercise during semaglutide or tirzepatide weight loss. And this drug class takes off more lean mass than dieting alone does.[12] No equivalent trial exists for the secretagogue question, and none is registered.
Not an interaction. A substitution.
What goes wrong here is not the two drugs colliding. Someone adds a secretagogue, treats it as the muscle step, and skips the training and protein that have trials behind them. Appetite suppression also makes hitting a protein target harder, at exactly the moment it matters more.
Growth hormone secretagogues also raise blood sugar in some people, and MK-677 is the one most often reported doing so. Anyone using a GLP-1 for blood sugar control as well as weight has reason to look at that compound more carefully than the injectable secretagogues.
The GLP-1 is the half you will feel. Its side effects are dominated by nausea, vomiting, diarrhea and constipation, mostly appearing in the week or two after each dose increase and settling over about four to six weeks. In the retatrutide trials, which push the same drug class hardest, about one in nine people stopped because of side effects. On a dummy injection it was one in twenty.[13]
The secretagogues have no registered trial collecting side effects systematically, so no comparable rates exist for them. Both are widely described as well tolerated, and that rests on an absence of reports rather than on anyone counting.
What people ask about this stack
Does adding ipamorelin or CJC-1295 preserve muscle on a GLP-1?
Nobody knows. No published randomized trial has tested any growth hormone secretagogue alongside semaglutide or tirzepatide, and none is registered. The mechanism argument is better than most in this category, since growth hormone's relationship to lean tissue is established pharmacology and the two drug classes do not interact. It remains an argument.
How much muscle do you actually lose?
A meta-analysis of weight loss generally puts it at 20 to 30 percent of weight lost, averaging about 1.3 kg. Figures specific to GLP-1 drugs run higher, and they come from preprints. Up to 9 percent of starting muscle on semaglutide. Around 11 percent on tirzepatide. Or 25 to 40 percent of total weight lost being lean tissue. Those two framings measure different things and are often quoted as though they were the same.
What does have evidence for keeping muscle?
Resistance training and adequate protein, together. A trial put 100 adults aged 55 to 80 into four groups for ten weeks of weight loss, testing higher protein and resistance training. Only the group doing both increased fat-free mass. A dose-response meta-analysis found strength gains rising with protein intake up to about 1.5 g/kg of body weight, and no strength gain at all from protein without training. People add compounds for the side effects too, most often BPC-157 for the gut symptoms.
Has that been tested in people on a GLP-1 specifically?
Not yet, and two trials are running. One measures preservation using ultrasound and a tracer that measures muscle directly. The other is a 232-person four-arm trial testing resistance exercise and protein separately and together alongside semaglutide or tirzepatide. Its published protocol states that no study has examined resistance exercise during GLP-1 weight loss, and that this drug class causes more lean mass loss than dieting alone.
Do the two drugs interact?
No. They work on completely different targets and do not touch each other. So this stack carries none of the interaction worries that come up elsewhere. The risk here is a different one. People add the second compound, treat it as the muscle step, and skip the training and protein that have evidence behind them.
What are the side effects?
The GLP-1 half carries them. Nausea, vomiting, diarrhea and constipation dominate, mostly appearing after each dose increase and settling over about four to six weeks. In trials of the same drug class at the aggressive end, roughly one in nine people stopped because of side effects against one in twenty on a dummy injection. The secretagogues have no registered trial collecting side effects systematically, so no comparable rates exist for them.
Is losing lean mass actually a problem?
Contested. One clinical view holds that it is the body adjusting to being smaller, not wasting. Most of what comes off is still fat. That view holds up less well for older adults, and for anyone who did not have much muscle to begin with. A phase 2 trial of a myostatin blocker cut the muscle share of weight lost from 30.2 percent to 14.6 percent. The problem is real enough for pharmaceutical companies to be targeting it. Compare against the other stacks.
What this page is built on
- 09Home-based resistance training during weight loss in people with overweight or obesity: a randomized controlled pilot trial. PMC12323239. Source for approximately 20 to 30 percent of weight lost being lean tissue and a meta-analytic average of about 1.3 kg lean body mass lost.
- 10Verreijen AM, Engberink MF, Memelink RG, et al. Effect of a high protein diet and/or resistance exercise on the preservation of fat free mass during weight loss in overweight and obese older adults: a randomized controlled trial. Nutrition Journal 2017. DOI 10.1186/s12937-017-0229-6. 100 adults aged 55 to 80, 2x2 factorial, 10 weeks. Only the combined high protein and resistance exercise group significantly increased fat-free mass, by 0.6 kg, p 0.011.
- 11Synergistic effect of increased total protein intake and strength training on muscle strength: a dose-response meta-analysis of randomized controlled trials. Sports Medicine Open 2022. DOI 10.1186/s40798-022-00508-w. Strength rises 0.72 percent per 0.1 g/kg/day increase in total protein up to 1.5 g/kg/day, with no further gain thereafter, and cannot be increased by protein alone without resistance training.
- 12LEAN mass preservation with resistance exercise and protein during GLP-1 therapy: trial protocol. PMC13110620. Single-center 6-month randomized trial at Dasman Diabetes Institute, 232 adults, four arms, protein target 1.6 g/kg/day. States that no studies have examined resistance exercise during semaglutide or tirzepatide-induced weight loss, which causes more pronounced lean mass loss than dietary interventions.
- 01Phase 2 trial of apitegromab with tirzepatide, Nature Medicine, reported via Medscape. Lean body mass 14.6 percent of total weight lost against 30.2 percent on placebo, with overall weight loss unchanged.
- 02GLP-1 and GIP receptor agonism in primary human myotubes. bioRxiv, DOI 10.64898/2026.07.20.739515.
- 03Dronedarone and metabolic syndrome. bioRxiv, DOI 10.64898/2026.07.20.739085. Source of the 25 to 40 percent figure.
- 04Lean body mass decline with tirzepatide against semaglutide in routine care. medRxiv, DOI 10.64898/2026.04.11.26350687. 670,422 people starting a GLP-1, 7,965 with lean body mass measured.
- 05Function and Lean Mass Preservation With Resistance Exercise During GLP-1RA Treatment. NCT07457437.
- 07TrimRX, ipamorelin stacking with GLP-1 medications. Source for the absence of published trials of the combination and the absence of pharmacological interaction between the two classes.
- 08Potere Health, GLP-1 and muscle loss. Source for the adaptive remodeling position.
- 13TRIUMPH-1 adverse event figures against placebo for the GLP-1 class at the aggressive end, including discontinuation of about 11.3 percent against 4.9 percent, and the onset and settling pattern of gastrointestinal effects.
- 06Peptide Decoding vendor pricing data, 12 September 2026. Single-compound listings only.